New Business

New Business

We are always searching for opportunities in strategic expansion as we consolidate our operations in Latin America and expand into major global markets. To schedule a meeting and learn about our partnership possibilities, send an email to partnership@eurofarma.com

Listen to the text Stop the audio

Business Development & Licensing

Strategic partnerships with other organizations and companies are fundamental to our growth and innovation strategy. Currently, products derived from partnerships and licenses account for around 10% of the company’s total earnings, which is equivalent to approximately R$ 732 million. In that sense, we are constantly looking for business opportunities in the many different therapeutic areas in order to develop innovative radical or incremental products and technologies. We are prepared to work under many different business models, whether involving distribution or licensing, including also co-development and technology transfer.   

J.P. Morgan 42nd Annual Healthcare Conference 2024
January 8th – 11th
Book your meeting with us and discuss new business opportunities!
partnership@eurofarma.com.br

M&A

We are always searching for opportunities in strategic expansion as we consolidate our operations in Latin America and expand into major global markets. We continuously seek partnerships and new business that support our growth strategy, including acquisitions, licensing and joint ventures.

To submit a proposal, contact us at:
novosnegocios@eurofarma.com.br

Out-licensing Opportunities

In addition to seeking to increase our portfolio through various partnership models, we also evaluate partners that wish to license our differentiated products. Available products:

  • Duomo HP® – Doxazosina + Finasterida | doxazosin + finasteride | Indications: Benign Prostatic Hyperplasia (BPH) and disease-related symptoms

  • Lugano®-Fluticasona + Formoterol | Indication: Regular treatment of adults and adolescents over 12 years of age with asthma

  • Tamiram® – Levofloxacino 750mg (nova concentração) | Acute Bacterial Sinusitis, Community-Acquired Pneumonia, Complicated Urinary Tract Infections, Acute Pyelonephritis

  • Versa® – Enoxaparina | Treatment of thrombosis, prevention of coagulation in cardiopulmonary bypass during hemodialysis, treatment of unstable angina and acute myocardial infarction when administered with acetylsalicylic acid

  • Heptar® – Heparina | Indication: Treatment and prophylaxis of thromboembolic disorders in patients with chronic kidney disease undergoing hemodialysis

Eurofarma's Experience